Drug Farm’s DF-003 shows early signal in ROSAH syndrome, but can ALPK1 inhibition hold up in pivotal testing?
Drug Farm’s DF-003 showed early Phase 1b benefit in ROSAH syndrome. Read what the ALPK1 data could change next.
Pharma & Biotech
Medical Devices & Diagnostics
Why MyGenius PRO could strengthen Bruker’s position in automated infectious disease diagnostics
Bruker Corporation has launched MyGenius PRO, a high-throughput sample-to-answer molecular diagnostics system, at ESCMID Global 2026 in Europe. The platform enters the infectious disease diagnostics market with IVDR assays for Cytomegalovirus, Epstein-Barr virus, and BK virus, positioning it squarely in transplant and immunocompromised patient testing where automation, turnaround time, and workflow reliability matter commercially as
Pharma & Biotech
Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.
Pharma & Biotech
How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe
European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.
Pharma & Biotech
Ensem Therapeutics puts pan-KRAS and WRN into focus as AACR 2026 sharpens its precision oncology pitch
Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.
Pharma & Biotech
Can Volastra Therapeutics turn KIF18A inhibition into a pan-cancer precision oncology platform?
Volastra Therapeutics unveils AACR 2026 biomarker and combination data for KIF18A inhibitors. Read what this means for oncology development.
Pharma & Biotech
Why Gilead’s Arcellx acquisition approval could reshape the multiple myeloma CAR-T race
Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.
Medical Devices & Diagnostics
Can PreludeDx and Quanterix turn AidaBREAST into a new standard for radiation therapy decisions
See why AidaBREAST could reshape breast cancer radiation decisions and put spatial proteomics closer to routine oncology use.
Pharma & Biotech
Why everyone watching neurology at AAN 2026 may end up talking about Acadia Pharmaceuticals
Acadia Pharmaceuticals heads to AAN 2026 with Daybue, Nuplazid, and ACP-711 data. Read what the updates could mean for its neurology strategy.
Pharma & Biotech
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.